With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The ...

The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...

Following a Wednesday morning event at Alnylam Pharmaceuticals on Commerce Way, Gov. Maura Healey spoke with The Sun ...

Despite market gains, Harbor Long-Term Growers ETF returned 6.90% (NAV) in Q3. Read the full report to understand key drivers ...

Harbor Long Term Growers ETF returned 6.90% in Q3 2025, underperforming its benchmark. Read the full report to discover key ...

Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced the nomination of CID-165, a first-in-class, ...

Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceuticals. -- Vir Biotechnology's chronic hepatitis delta ...

Vir Biotechnology is handing off certain commercial rights for its hepatitis D program to European specialty pharma Norgine ...

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Kevin Finney, President ...

The Scottish investment trust has warned the possibility of its board being ousted this time has increased significantly ...